Navigation Links
ADVENTRX Pharmaceuticals Announces Financing
Date:6/8/2009

SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a single institutional investor, representing gross proceeds of approximately $2 million. The preferred stock is convertible into shares of ADVENTRX's common stock at the option of the investor at a price of $0.1105 per share.

The investor will also receive warrants to purchase 8,116,290 shares of ADVENTRX's common stock. The warrants have an exercise price of $0.15 per share and are exercisable at any time after the six-month anniversary of the closing of the transaction and before the fifth anniversary of such initial exercise date. The closing of the offering is expected to take place on or before June 12, 2009, subject to the satisfaction of customary closing conditions. ADVENTRX plans to use the net proceeds from the offering to fund activities related to seeking FDA approval to market ANX-530 (vinorelbine emulsion) in the United States, including manufacturing-related activities, and for general corporate purposes, including general and administrative expenses.

The shares and warrants are being offered by ADVENTRX pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC"). A prospectus supplement relating to the offering will be filed with the SEC. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sa
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
2. ADVENTRX Announces Further Cost-Cutting Measures
3. ADVENTRX Provides Update on Strategic Transaction Process
4. ADVENTRX Announces Further Cost-Cutting Measures
5. ADVENTRX Exploring Strategic Options
6. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
7. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
8. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
9. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
10. ADVENTRX Settles Dispute With Former Licensee
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 VG Energy, an agricultural ... DAK Renewable Research to conduct field trials using ... Energy is a majority owned subsidiary of VG ... VG Energy,s exclusively licensed compound LipidMax selectively inhibits ... in plants, possessing a wide variety of applications ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
(Date:5/23/2013)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... a teleconference to discuss its First Quarter 2013 financial ... information is provided below: Date: Thursday, May ... Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 ( ... For those unable to participate in the ...
(Date:5/23/2013)... Tucson, Ariz. (PRWEB) May 23, 2013 ... world’s first and only FDA, Health Canada and CE ... Glasgow Science Centre in Scotland, which boasts more than ... Total Artificial Heart powered by the Freedom® portable ... one of the most advanced exhibitions of its kind. ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
... CITY, Mo., Aug. 28 Truman Medical Centers (TMC),became ... to install the,Siemens SOMATOM Definition AS 128 slice CT ... adaptive scanner, providing exceptional image,quality with minimal radiation exposure ... first medical facilities in the country to have this,truly, ...
... (NYSE: BRL ) today announced that its ... U.S. Food & Drug Administration,(FDA) to manufacture and ... (galantamine hydrobromide), 4 mg, 8 mg and 12 ... tablets product immediately., Barr filed an Abbreviated ...
... Brussels: THR), a biotechnology company focused on innovative,treatments ... today issuing a,business update and its financial results ... During the first half of 2008, ThromboGenics ... positioned the Company to successfully pursue the,next stage ...
Cached Biology Technology:Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the World's First Adaptive 128-slice CT Scanner 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5
(Date:5/23/2013)... be the world,s most popular fruit, can be made ... purple GM varieties. , "Working with GM tomatoes ... addition of a specific compound, allows us to pinpoint ... Cathie Martin from the John Innes Centre. , The ... flavour, health and shelf life characteristics because even higher ...
(Date:5/23/2013)... nucleosomes in the cell nucleus makes it unavailable ... in Munich now describes a mechanism that allows ... for transcription. , In higher organisms the genomic ... around disk-shaped particles called nucleosomes, each consisting of ... accommodating two loops of DNA. Packed in this ...
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
Breaking Biology News(10 mins):The world's favorite fruit only better-tasting and longer-lasting 2Biochemistry: Unspooling DNA from nucleosomal disks 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... a spin-off of the Universitat Autònoma de Barcelona, in ... developed an artificial cellular model which faithfully reproduces the ... the carrying out of various lines of research related ... use live animals. , The basic structure of skin ...
... Pretreatment with double-dose anticlotting medication just before percutaneous coronary ... and cardiac death by half, according to a study ... Society for Cardiovascular Angiography and Interventions (SCAI), May 9?2, ... giving patients at least 600 mg of clopidogrel before ...
... Pigs carry hepatitis E virus (HEV), which they can pass ... Online Open Access journal BMC Veterinary Research says that pigs ... infection. The scenario humans need to worry about would occur ... rates, there is actually a higher chance pigs will pass ...
Cached Biology News:High-dose anticlotting drug cuts heart attack, death risk in half 2